Intravenous COTI-2 In Combination With Doxil(R) Is More Effective Than Treatment With Doxil Alone In An Animal Model Of Human Ovarian Cancer

Main Category: Ovarian Cancer
Also Included In: Cancer / Oncology
Article Date: 05 Jul 2009 - 0:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Critical Outcome Technologies Inc. (TSX VENTURE:COT), announced positive results today from combination agent animal experiments carried out at a prominent American cancer research facility. The results provide strong supportive evidence for the continued evaluation of COTI-2 in combination with conventional single agent therapy for the treatment of ovarian cancer:

- Tumor growth inhibition was significantly greater in the COTI-2 plus Doxil treated animals compared to the Doxil control group treated animals with:

-- 12.5 mg/kg COTI-2 + 2 mg/kg Doxil causing 57% tumor growth inhibition

-- 25 mg/kg COTI-2 + 2 mg/kg Doxil causing 54% tumor growth inhibition

-- 2mg/kg Doxil control causing 29% tumor growth inhibition

- The effectiveness of the combination treatments with COTI-2 was apparent early in the study (day 4) and increased throughout the remainder of the study.

- Combination treatments were well tolerated.

"We are delighted to see that intravenous COTI-2 in combination with Doxil showed superior treatment results compared to Doxil alone as measured by significant tumor growth inhibition in an animal model of an aggressive human ovarian cancer (A2780). These results are significant because they add to the impressive data set of COTI-2, showing effectiveness, particularly in combination with first and second line agents, against multiple cancers and low toxicity," said Dr. Wayne Danter, President and Chief Scientific Officer of Critical Outcome Technologies Inc. (COTI).

"COTI will share this new data with parties who have expressed interest in a commercial partnership related to COTI-2," said Mr. Michael Cloutier, Chief Executive Officer of COTI.

The Company intends to repeat this study using an oral formulation of COTI-2 to compare the effectiveness of oral COTI-2 in an animal model of human disease.

The Company is also advising of a correction to its June 10, 2009 press release, which announced a brokered private placement as this should have read a non-brokered private placement.

Source
Critical Outcome Technologies Inc. (COTI)